2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

키워드

참고문헌 (415)

1. Gines P, "Compensated cirrhosis: natural history and prognostic factors", Hepatology, 7, pp.122~128 (1987)[DOI]
2. D'Amico G, "Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies", J Hepatol, 44, pp.217~231 (2006)[DOI]
3. Guyatt GH, "GRADE: an emerging consensus on rating quality of evidence and strength of recommendations", BMJ, 336, pp.924~926 (2008)[DOI]
4. Runyon BA, "The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites", Ann Intern Med, 117, pp.215~220 (1992)[DOI]
5. Shaikh MA, "Frequency of causes of ascites in patients admitted at medical unit of a tertiary medical care facility", J Ayub Med Coll Abbottabad, 22, pp.88~92 (2010)
6. Runyon BA, "Ascites;Diseases of the Liver", pp.990~1015 (1993), Lippincott
7. 황보영, "천자검사를 받은 복수 환자의 원인 분석", Clinical and Molecular Hepatology, 13(2), pp.185~195 (2007), 대한간학회
8. Cattau EL Jr, "The accuracy of the physical examination in the diagnosis of suspected ascites", JAMA, 247, pp.1164~1166 (1982)[DOI]
9. Kuiper JJ, "Review article: management of ascites and associated complications in patients with cirrhosis", Aliment Pharmacol Ther, 26(Suppl 2), pp.183~193 (2007)
10. Sheer TA, "Usefulness of serum N-terminal- ProBNP in distinguishing ascites due to cirrhosis from ascites due to heart failure", J Clin Gastroenterol, 44, pp.e23~e26 (2010)[DOI]
11. Runyon BA, "Care of patients with ascites", N Engl J Med, 330, pp.337~342 (1994)[DOI]
12. Borzio M, "Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study", Dig Liver Dis, 33, pp.41~48 (2001)[DOI]
13. European Association for the Study of the Liver, "EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis", J Hepatol, 53, pp.397~417 (2010)[DOI]
14. Sakai H, "Choosing the location for non-image guided abdominal paracentesis", Liver Int, 25, pp.984~986 (2005)[DOI]
15. Webster ST, "Hemorrhagic complications of large volume abdominal paracentesis", Am J Gastroenterol, 91, pp.366~368 (1996)
16. Runyon BA, "Paracentesis of ascitic fluid. A safe procedure", Arch Intern Med, 146, pp.2259~2261 (1986)[DOI]
17. Pache I, "Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease", Aliment Pharmacol Ther, 21, pp.525~529 (2005)[DOI]
18. Liebowitz HR, "Hazards of abdominal paracentesis in the cirrhotic patient", N Y State J Med, 62, pp.2223~2229 (1962)
19. Serbin RA, "Fatal hemorrhage from paracentesis; a case of Cruveilhier Baumgarten syndrome", Gastroenterology, 30, pp.127~129 (1956)
20. Thomson A, "Serious hemorrhage complicating diagnostic abdominal paracentesis", J Clin Gastroenterol, 26, pp.306~308 (1998)[DOI]
21. Arnold C, "Acute hemoperitoneum after large-volume paracentesis", Gastroenterology, 113, pp.978~982 (1997)[DOI]
22. Qureshi WA, "An unusual complication of paracentesis", Am J Gastroenterol, 87, pp.1209~1211 (1992)
23. 박연지, "Transcatheter coil embolization of the inferior epigastric artery in a huge abdominal wall hematoma caused by paracentesis in a patient with liver cirrhosis", Clinical and Molecular Hepatology, 17(3), pp.233~237 (2011), 대한간학회
24. 강종원, "혈관색전술로 치료한 측복벽 혈종 1예", 대한소화기학회지, 59(2), pp.185~188 (2012), 대한소화기학회
25. Martinet O, "Delayed hemoperitoneum following large-volume paracentesis in a patient with cirrhosis and ascites", Dig Dis Sci, 45, pp.357~358 (2000)[DOI]
26. McGibbon A, "An evidence-based manual for abdominal paracentesis", Dig Dis Sci, 52, pp.3307~3315 (2007)[DOI]
27. Grabau CM, "Performance standards for therapeutic abdominal paracentesis", Hepatology, 40, pp.484~488 (2004)
28. Mannucci PM, "Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No", J Thromb Haemost, 4, pp.721~723 (2006)[DOI]
29. Caldwell SH, "Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management", Hepatology, 44, pp.1039~1046 (2006)[DOI]
30. Jeffries MA, "Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis", Am J Gastroenterol, 94, pp.2972~2976 (1999)[DOI]
31. Evans LT, "Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites", Hepatology, 37, pp.897~901 (2003)[DOI]
32. Runyon BA, "Ascitic fluid analysis in malignancy-related ascites", Hepatology, 8, pp.1104~1109 (1988)[DOI]
33. Ahadi M, "Diagnostic value of carcinoembryonic antigen in malignancy-related ascites: systematic review and meta-analysis", Acta Gastroenterol Belg, 77, pp.418~424 (2014)
34. Sathar MA, "Ascitic fluid gamma interferon concentrations and adenosine deaminase activity in tuberculous peritonitis", Gut, 36, pp.419~421 (1995)[DOI]
35. Saleh MA, "Use of adenosine deaminase measurements and QuantiFERON in the rapid diagnosis of tuberculous peritonitis", J Med Microbiol, 61, pp.514~519 (2012)[DOI]
36. Portillo-Gomez L, "Rapid and efficient detection of extra-pulmonary Mycobacterium tuberculosis by PCR analysis", Int J Tuberc Lung Dis, 4, pp.361~370 (2000)
37. Inadomi JM, "The laparoscopic evaluation of ascites", Gastrointest Endosc Clin N Am, 11, pp.79~91 (2001)[DOI]
38. Menzies RI, "Laparoscopic diagnosis of ascites in Lesotho", Br Med J (Clin Res Ed), 291, pp.473~475 (1985)[DOI]
39. Singh MM, "Tuberculous peritonitis. An evaluation of pathogenetic mechanisms, diagnostic procedures and therapeutic measures", N Engl J Med, 281, pp.1091~1094 (1969)[DOI]
40. Voigt MD, "Diagnostic value of ascites adenosine deaminase in tuberculous peritonitis", Lancet, 1, pp.751~754 (1989)
41. Bhargava DK, "Adenosine deaminase (ADA) in peritoneal tuberculosis: diagnostic value in ascitic fluid and serum", Tubercle, 71, pp.121~126 (1990)[DOI]
42. Ribera E, "Diagnostic value of ascites gamma interferon levels in tuberculous peritonitis. Comparison with adenosine deaminase activity", Tubercle, 72, pp.193~197 (1991)[DOI]
43. Dwivedi M, "Value of adenosine deaminase estimation in the diagnosis of tuberculous ascites", Am J Gastroenterol, 85, pp.1123~1125 (1990)
44. Hillebrand DJ, "Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States", Hepatology, 24, pp.1408~1412 (1996)[DOI]
45. 이준성, "결핵성 복막염 진단을 위한 복수 Adenosine Deaminase 측정의 임상적 유용성", 대한소화기학회지, 41(2) (2003), 대한소화기학회
46. Liao YJ, "Adenosine deaminase activity in tuberculous peritonitis among patients with underlying liver cirrhosis", World J Gastroenterol, 18, pp.5260~5265 (2012)
47. Cappell MS, "A multicenter, case-controlled study of the clinical presentation and etiology of ascites and of the safety and clinical efficacy of diagnostic abdominal paracentesis in HIV seropositive patients", Am J Gastroenterol, 89, pp.2172~2177 (1994)
48. Akriviadis EA, "Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis", Gastroenterology, 98, pp.127~133 (1990)[DOI]
49. Wu SS, "Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation", J Hepatol, 34, pp.215~221 (2001)
50. Ridinger HA, "Urinary ascites and renal failure from unrecognized bladder rupture", Am J Med, 125, pp.e1~e2 (2012)[DOI]
51. 우정주, "N-terminal Pro B-type Natriuretic Peptide and the Evaluation of Cardiac Dysfunction and Severity of Disease in Cirrhotic Patients", Yonsei Medical Journal, 49(4), pp.625~631 (2008), 연세대학교의과대학
52. Runyon BA, "Malignancy-related ascites and ascitic fluid "humoral tests of malignancy"", J Clin Gastroenterol, 18, pp.94~98 (1994)[DOI]
53. Zuckerman E, "Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis", Am J Gastroenterol, 94, pp.1613~1618 (1999)[DOI]
54. Garg H, "Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure", Hepatology, 53, pp.774~780 (2011)[DOI]
55. Runyon BA, "Management of adult patients with ascites due to cirrhosis: an update", Hepatology, 49, pp.2087~2107 (2009)[DOI]
56. Veldt BJ, "Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing", J Hepatol, 36, pp.93~98 (2002)
57. Yamini D, "Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis", Alcohol Alcohol, 49, pp.453~456 (2014)[DOI]
58. Addolorato G, "Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study", Lancet, 370, pp.1915~1922 (2007)[DOI]
59. 문원, "라미부딘 내성을 보인 비대상성 간경변증 환자에서 아데포비어의 효과와 안전성; 대상성 간질환군과의 비교", Clinical and Molecular Hepatology, 11(2005), pp.125~134 (2005), 대한간학회
60. Shim JH, "Efficacy of entecavir in treatment-naive patients with hepatitis B virusrelated decompensated cirrhosis", J Hepatol, 52, pp.176~182 (2010)[DOI]
61. Yao FY, "Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection", J Hepatol, 33, pp.301~307 (2000)[DOI]
62. Manolakopoulos S, "Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAgnegative chronic hepatitis B and significant portal hypertension", J Hepatol, 51, pp.468~474 (2009)[DOI]
63. Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)[DOI]
64. Afdhal N, "Sofosbuvir and ribavirin for the treatment chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety", J Hepatol, 60, pp.S28~ (2014)
65. 김태엽, "Sarcopenia as a Useful Predictor for Long-Term Mortality in Cirrhotic Patients with Ascites", Journal of Korean Medical Science, 29(9), pp.1253~1259 (2014), 대한의학회
66. Plauth M, "ESPEN guidelines on Parenteral Nutrition: hepatology", Clin Nutr, 28, pp.436~444 (2009)[DOI]
67. Plauth M, "ESPEN guidelines on Enteral Nutrition: liver disease", Clin Nutr, 25, pp.285~294 (2006)[DOI]
68. Lochs H, "Liver cirrhosis: rationale and modalities for nutritional support--the European Society of Parenteral and Enteral Nutrition consensus and beyond", Curr Opin Clin Nutr Metab Care, 2, pp.345~349 (1999)[DOI]
69. Swart GR, "Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver", BMJ, 299, pp.1202~1203 (1989)[DOI]
70. Zillikens MC, "Nocturnal oral glucose supplementation. The effects on protein metabolism in cirrhotic patients and in healthy controls", J Hepatol, 17, pp.377~383 (1993)[DOI]
71. Chang WK, "Effects of extracarbohydrate supplementation in the late evening on energy expenditure and substrate oxidation in patients with liver cirrhosis", JPEN J Parenter Enteral Nutr, 21, pp.96~99 (1997)[DOI]
72. Plank LD, "Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial", Hepatology, 48, pp.557~566 (2008)[DOI]
73. Sorrentino P, "Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis", J Gastroenterol Hepatol, 27, pp.813~822 (2012)[DOI]
74. Stickel F, "Review article: nutritional therapy in alcoholic liver disease", Aliment Pharmacol Ther, 18, pp.357~373 (2003)[DOI]
75. DiCecco SR, "Nutrition in alcoholic liver disease", Nutr Clin Pract, 21, pp.245~254 (2006)[DOI]
76. Grungreiff K, "The role of zinc in liver cirrhosis", Ann Hepatol, 15, pp.7~16 (2016)
77. Fialla AD, "Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis", Liver Int, 35, pp.2072~2078 (2015)[DOI]
78. Shiozawa S, "Impact of branched-chain amino acid-enriched nutrient on liver cirrhosis with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization in Barcelona Clinic Liver Cancer Stage B: a prospective study", J Nippon Med Sch, 83, pp.248~256 (2016)[DOI]
79. Wong F, "Management of ascites in cirrhosis", J Gastroenterol Hepatol, 27, pp.11~20 (2012)[DOI]
80. Moore KP, "Guidelines on the management of ascites in cirrhosis", Gut, 55(Suppl 6), pp.vi1~vi12 (2006)
81. Suk KT, "Revision and update on clinical practice guideline for liver cirrhosis", Korean J Hepatol, 18, pp.1~21 (2012)[DOI]
82. Reynolds TB, "Ascites", Clin Liver Dis, 4, pp.151~168 (2000)[DOI]
83. Santos J, "Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety", J Hepatol, 39, pp.187~192 (2003)[DOI]
84. Angeli P, "Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites", Hepatology, 19, pp.72~79 (1994)[DOI]
85. Gentilini P, "Torasemide in the treatment of patients with cirrhosis and ascites", Cardiovasc Drugs Ther, 7(Suppl 1), pp.81~85 (1993)[DOI]
86. Bernardi M, "Optimum use of diuretics in managing ascites in patients with cirrhosis", Gut, 59, pp.10~11 (2010)[DOI]
87. Angeli P, "Combined versus sequential diuretic treatment of ascites in non azotaemic patients with cirrhosis: results of an open randomised clinical trial", Gut, 59, pp.98~104 (2010)[DOI]
88. Korean Association for the Study of the Liver, "Treatment guideline of complications of liver cirrhosis", Korean J Hepatol, 11(Suppl 4), pp.S115~S138 (2005)
89. Pockros PJ, "Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema", Gastroenterology, 90, pp.1827~1833 (1986)[DOI]
90. Dougher CE, "Spot urine sodium measurements do not accurately estimate dietary sodium intake in chronic kidney disease", Am J Clin Nutr, 104, pp.298~305 (2016)[DOI]
91. Stiehm AJ, "Detection of diureticresistace or diuretic-sensitivity by the spot urine Na+", K+ ratio in 729 specimens from cirrhotics with ascites: approximately 90% accuracy as compared to 24-hour urine Na+ excretion, 2002, pp.36, 222A~
92. 박재은, "복수를 동반한 간경변증 환자에서 임의뇨 Na", K 비의 진단적 유용성: 예비연구, 2010, pp.16(1), 66~74[DOI]
93. Marchesini G, "Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind caseincontrolled trial. The Italian Multicenter Study Group", J Hepatol, 11, pp.92~101 (1990)[DOI]
94. Fukui H, "Evidence-based clinical practice guidelines for liver cirrhosis 2015", J Gastroenterol, 51, pp.629~650 (2016)[DOI]
95. Hirsch S, "Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis", JPEN J Parenter Enteral Nutr, 17, pp.119~124 (1993)[DOI]
96. Yatsuhashi H, "Anti-hypoalbuminemic effect of branched-chain amino acid granules in patients with liver cirrhosis is independent of dietary energy and protein intake", Hepatol Res, 41, pp.1027~1035 (2011)[DOI]
97. Kawamura E, "A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: validation using prognostic markers for preliver transplant status", Liver Transpl, 15, pp.790~797 (2009)[DOI]
98. Kitajima Y, "Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis", J Gastroenterol, 53, pp.427~437 (2018)[DOI]
99. Ruiz-Margain A, "Effect of a high-protein, high-fiber diet plus supplementation with branched-chain amino acids on the nutritional status of patients with cirrhosis", Rev Gastroenterol Mex, 83, pp.9~15 (2018)
100. Kikuchi Y, "A randomized clinical trial of preoperative administration of branched-chain amino acids to prevent postoperative ascites in patients with liver resection for hepatocellular carcinoma", Ann Surg Oncol, 23, pp.3727~3735 (2016)[DOI]
101. Park JG, "Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: a Korean nationwide, multicenter, retrospective, observational, cohort study", Medicine (Baltimore), 96, pp.e6580~ (2017)[DOI]
102. Takaguchi K, "Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis", Hepatol Res, 43, pp.459~466 (2013)[DOI]
103. 이준성, "Albumin for End-Stage Liver Disease", The Korean Journal of Internal Medicine, 27(1), pp.13~19 (2012), 대한내과학회
104. Gentilini P, "Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial", J Hepatol, 30, pp.639~645 (1999)[DOI]
105. Bernardi M, "Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials", Hepatology, 55, pp.1172~1181 (2012)[DOI]
106. Sort P, "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis", N Engl J Med, 341, pp.403~409 (1999)[DOI]
107. Romanelli RG, "Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial", World J Gastroenterol, 12, pp.1403~1407 (2006)[DOI]
108. Italian Association for the Study of the Liver (AISF), "AISFSIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis", Dig Liver Dis, 48, pp.4~15 (2016)[DOI]
109. Tito L1, "Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites", Gastroenterology, 98, pp.146~151 (1990)[DOI]
110. Hong SP, "Effects of large volume paracentesis", Korean J Med, 40, pp.147~152 (1991)
111. Arroyo V, "Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club", Hepatology, 23, pp.164~176 (1996)[DOI]
112. Moore KP, "The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club", Hepatology, 38, pp.258~266 (2003)
113. Choi CH, "Long-term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: a randomized prospective study", J Gastroenterol Hepatol, 20, pp.1215~1222 (2005)[DOI]
114. 심유진, "Dietary sodium intake in young Korean adults and its relationship with eating frequency and taste preference", Nutrition Research and Practice, 7(3), pp.192~198 (2013), 한국영양학회[DOI]
115. Gines A, "Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis", Gastroenterology, 111, pp.1002~1010 (1996)[DOI]
116. Moreau R, "Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid", Liver Int, 26, pp.46~54 (2006)[DOI]
117. Singh V, "Midodrine versus albumin in the prevention of paracentesisinduced circulatory dysfunction in cirrhotics: a randomized pilot study", Am J Gastroenterol, 103, pp.1399~1405 (2008)[DOI]
118. Lata J, "The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites--a randomized multicentric study", Hepatogastroenterology, 54, pp.1930~1933 (2007)
119. Serste T, "Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study", J Hepatol, 55, pp.794~799 (2011)[DOI]
120. Serste T, "Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites", Hepatology, 52, pp.1017~1022 (2010)[DOI]
121. Llach J, "Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites", Gastroenterology, 94, pp.482~487 (1988)[DOI]
122. Singh V, "Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study", Am J Gastroenterol, 108, pp.560~567 (2013)[DOI]
123. Singh V, "Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study", J Hepatol, 56, pp.348~354 (2012)[DOI]
124. Yang YY, "Association of the G-protein and <TEX>${\alpha}2$<", TEX>-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial, 2010, pp.59, 1545~1553
125. Wong F, "Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity", Gut, 61, pp.108~116 (2012)[DOI]
126. Rossle M, "A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites", N Engl J Med, 342, pp.1701~1707 (2000)[DOI]
127. Salerno F, "Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data", Gastroenterology, 133, pp.825~834 (2007)[DOI]
128. Gines P, "Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis", Gastroenterology, 123, pp.1839~1847 (2002)[DOI]
129. Sanyal AJ, "The North American study for the treatment of refractory ascites", Gastroenterology, 124, pp.634~641 (2003)[DOI]
130. Miraglia R, "Transjugular intrahepatic portosystemic shunts in patients with cirrhosis with refractory ascites: comparison of clinical outcomes by using 8-and 10-mm PTFE-covered Stents", Radiology, 284, pp.281~288 (2017)[DOI]
131. Bai M, "TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis", World J Gastroenterol, 20, pp.2704~2714 (2014)[DOI]
132. Bureau C, "Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites", Gastroenterology, 152, pp.157~163 (2017)[DOI]
133. Berry K, "Association between transjugular intrahepatic portosystemic shunt and survival in patients with cirrhosis", Clin Gastroenterol Hepatol, 14, pp.118~123 (2016)[DOI]
134. Hosokawa I, "Outcomes of surgical shunts and transjugular intrahepatic portasystemic stent shunts for complicated portal hypertension", Br J Surg, 104, pp.443~451 (2017)[DOI]
135. Rabie R, "The effect of cirrhotic cardiomyopathy on the post-TIPS outcome of patients treated for complications of portal hypertension", Hepatology, 44, pp.444A~ (2006)[DOI]
136. Azoulay D, "Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study", Hepatology, 19, pp.129~132 (1994)[DOI]
137. Michl P, "Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: effects in patients with organic or functional renal failure", Scand J Gastroenterol, 35, pp.654~658 (2000)[DOI]
138. 서주희, "Predictors of Refractory Ascites Development in Patients with Hepatitis B Virus-Related Cirrhosis Hospitalized to Control Ascitic Decompensation", Yonsei Medical Journal, 54(1), pp.145~153 (2013), 연세대학교의과대학[DOI]
139. Heuman DM, "Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death", Hepatology, 40, pp.802~810 (2004)[DOI]
140. Durand F, "Assessment of prognosis of cirrhosis", Semin Liver Dis, 28, pp.110~122 (2008)[DOI]
141. Luca A, "An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis", Liver Transpl, 13, pp.1174~1180 (2007)[DOI]
142. Trotter J, "Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS)", Dig Dis Sci, 50, pp.1356~1360 (2005)[DOI]
143. Lenaerts A, "Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites", Gastroenterol Clin Biol, 29, pp.1137~1142 (2005)[DOI]
144. Gines P, "Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites", N Engl J Med, 325, pp.829~835 (1991)[DOI]
145. Bureau C, "Alfapump(R) system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study", J Hepatol, 67, pp.940~949 (2017)[DOI]
146. Zaak D, "Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites", Z Gastroenterol, 39, pp.5~10 (2001)[DOI]
147. Graziotto A, "Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial", Dig Dis Sci, 42, pp.1708~1714 (1997)[DOI]
148. Runyon BA, "Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012", Hepatology, 57, pp.1651~1653 (2013)[DOI]
149. 김종훈, "The Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis", The Korean Journal of Internal Medicine, 24(2), pp.106~112 (2009), 대한내과학회
150. Angeli P, "Hyponatremia in cirrhosis: results of a patient population survey", Hepatology, 44, pp.1535~1542 (2006)[DOI]
151. Ge PS, "Treatment of patients with cirrhosis", N Engl J Med, 375, pp.2104~2105 (2016)
152. Abelmann WH, "Hyperdynamic circulation in cirrhosis: a historical perspective", Hepatology, 20, pp.1356~1358 (1994)[DOI]
153. 김문영, "간경변 및 문맥압 항진증에서 과역동 혈역학 변화", 대한소화기학회지, 54(3), pp.143~148 (2009), 대한소화기학회
154. Battista S, "Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins", J Hepatol, 26, pp.75~80 (1997)[DOI]
155. Arkenau HT, "Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation", Z Gastroenterol, 40, pp.907~913 (2002)[DOI]
156. Hebert RL, "PGE2 inhibits AVP-induced water flow in cortical collecting ducts by protein kinase C activation", Am J Physiol, 259(2), pp.F318~F325 (1990)
157. Bichet D, "Role of vasopressin in abnormal water excretion in cirrhotic patients", Ann Intern Med, 96, pp.413~417 (1982)[DOI]
158. Adrogue HJ, "Hyponat remia", N Engl J Med, 342, pp.1581~1589 (2000)[DOI]
159. Gerbes AL, "Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial", Gastroenterology, 124, pp.933~939 (2003)[DOI]
160. Wong F, "A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebocontrolled trial", Hepatology, 37, pp.182~191 (2003)[DOI]
161. McCormick PA, "Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites", Gut, 31, pp.204~207 (1990)[DOI]
162. Martinez-Castelao A, "Conivaptan (Yamanouchi)", Curr Opin Investig Drugs, 3, pp.89~95 (2002)
163. Wada K, "Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction", Eur J Pharmacol, 450, pp.169~177 (2002)[DOI]
164. Fernandez-Varo G, "Effect of the V1a", V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites, 2003, pp.38, 755~761
165. Hline SS, "Conivaptan: a step forward in the treatment of hyponatremia?", Ther Clin Risk Manag, 4, pp.315~326 (2008)[DOI]
166. Dominguez M, "Efficacy of 3% saline vs. conivaptan in achieving hyponatremia treatment goals", Methodist Debakey Cardiovasc J, 9, pp.49~53 (2013)[DOI]
167. Ghali JK, "Efficacy and safety of oral conivaptan: a V1A", V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia, 2006, pp.91, 2145~2152
168. Marbury T, "Pharmacokinetics of conivaptan use in patients with severe hepatic impairment", Drug Des Devel Ther, 11, pp.373~382 (2017)[DOI]
169. Soupart A, "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist", Clin J Am Soc Nephrol, 1, pp.1154~1160 (2006)[DOI]
170. Gines P, "Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial", Hepatology, 48, pp.204~213 (2008)[DOI]
171. Wong F, "Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis", J Hepatol, 53, pp.283~290 (2010)[DOI]
172. Konstam MA, "Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial", JAMA, 297, pp.1319~1331 (2007)[DOI]
173. Cardenas A, "Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis", J Hepatol, 56, pp.571~578 (2012)[DOI]
174. Berl T, "Oral tolvaptan is safe and effective in chronic hyponatremia", J Am Soc Nephrol, 21, pp.705~712 (2010)[DOI]
175. Torres VE, "Tolvaptan in patients with autosomal dominant polycystic kidney disease", N Engl J Med, 367, pp.2407~2418 (2012)[DOI]
176. Watkins PB, "Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database", Drug Saf, 38, pp.1103~1113 (2015)[DOI]
177. "Guidance for industry; Drug-induced liver injury: premarketing clinical evaluation"[URL]
178. "Assessment report"[URL]
179. "Report on the Deliberation Results"[URL]
180. Biggins SW, "Serum sodium predicts mortality in patients listed for liver transplantation", Hepatology, 41, pp.32~39 (2005)[DOI]
181. Guevara M, "Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration", Liver Int, 30, pp.1137~1142 (2010)[DOI]
182. Pereira G, "Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study", J Hepatol, 56, pp.1040~1046 (2012)[DOI]
183. Kim WR, "Hyponatremia and mortality among patients on the liver-transplant waiting list", N Engl J Med, 359, pp.1018~1026 (2008)[DOI]
184. Yun BC, "Impact of pretransplant hyponatremia on outcome following liver transplantation", Hepatology, 49, pp.1610~1615 (2009)[DOI]
185. Caly WR, "A prospective study of bacterial infections in patients with cirrhosis", J Hepatol, 18, pp.353~358 (1993)[DOI]
186. Tandon P, "Bacterial infections, sepsis, and multiorgan failure in cirrhosis", Semin Liver Dis, 28, pp.26~42 (2008)[DOI]
187. Rimola A, "Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club", J Hepatol, 32, pp.142~153 (2000)
188. Runyon BA, "Optimization of ascitic fluid culture technique", Gastroenterology, 95, pp.1351~1355 (1988)[DOI]
189. Kim SU, "Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis", J Gastroenterol Hepatol, 25, pp.122~128 (2010)[DOI]
190. Pelletier G, "Asymptomatic bacterascites: is it spontaneous bacterial peritonitis?", Hepatology, 14, pp.112~115 (1991)[DOI]
191. Runyon BA, "Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis", Hepatology, 12(4), pp.710~715 (1990)[DOI]
192. Rerknimitr R, "A comparison of diagnostic efficacies among different reagent strips and automated cell count in spontaneous bacterial peritonitis", J Gastroenterol Hepatol, 25, pp.946~950 (2010)[DOI]
193. Nousbaum JB, "Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis", Hepatology, 45, pp.1275~1281 (2007)[DOI]
194. Farmer AD, "Leucocyte esterase reagent strips for the diagnosis of spontaneous bacterial peritonitis: a systematic review by Koulaouzidis et al", Eur J Gastroenterol Hepatol, 21, pp.1102~ (2009)[DOI]
195. Soriano G, "Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management", J Hepatol, 52, pp.39~44 (2010)[DOI]
196. Runyon BA, "Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid", Hepatology, 4, pp.447~450 (1984)[DOI]
197. Teh SH, "Risk factors for mortality after surgery in patients with cirrhosis", Gastroenterology, 132, pp.1261~1269 (2007)[DOI]
198. 박문경, "자발세균복막염의 원인 균주 및 항균제 내성률의 변화: 최근 12년간 배양된 균주의 분석", Clinical and Molecular Hepatology, 13(3), pp.370~377 (2007), 대한간학회
199. Kim JH, "Predictive factors of spontaneous bacterial peritonitis caused by grampositive bacteria in patients with cirrhosis", Medicine (Baltimore), 95, pp.e3489~ (2016)[DOI]
200. Cheong HS, "Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis", Clin Infect Dis, 48, pp.1230~1236 (2009)[DOI]
201. 허정, "Clinical Features and Prognosis of Spontaneous Bacterial Peritonitis in Korean Patients with Liver Cirrhosis: A Multicenter Retrospective Study", Gut and Liver, 3(3), pp.197~204 (2009), 거트앤리버 소화기연관학회협의회
202. Pei Chuan Tsung, "Predictive factors that influence the survival rates in liver cirrhosis patients with spontaneous bacterial peritonitis", Clinical and Molecular Hepatology, 19(2), pp.131~139 (2013), 대한간학회[DOI]
203. Runyon BA, "Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis", Dig Dis Sci, 36, pp.1782~1786 (1991)[DOI]
204. Felisart J, "Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections", Hepatology, 5, pp.457~462 (1985)[DOI]
205. Ricart E, "Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients", J Hepatol, 32, pp.596~602 (2000)[DOI]
206. Tuncer I, "Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis", Hepatogastroenterology, 50, pp.1426~1430 (2003)
207. Yim HJ, "Comparison of efficacy of cefotaxime, ceftriaxone, and ciprofloxacin for the treatment of spontaneous bacterial peritonitis in patients with liver cirrhosis: a randomized controlled trial", J Hepatol, 66, pp.S374~S375 (2017)
208. Franca A, "Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients", J Gastroenterol, 37, pp.119~122 (2002)[DOI]
209. Gomez-Jimenez J, "Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients", Antimicrob Agents Chemother, 37, pp.1587~1592 (1993)[DOI]
210. Baskol M, "Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients", J Clin Gastroenterol, 37, pp.403~405 (2003)[DOI]
211. Terg R, "Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study", J Hepatol, 33, pp.564~569 (2000)[DOI]
212. Navasa M, "Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis", Gastroenterology, 111, pp.1011~1017 (1996)[DOI]
213. Kim J, "Risk factor of community-onset spontaneous bacterial peritonitis caused by fluoroquinolone-resistant Escherichia coli in patients with cirrhosis", Liver Int, 34, pp.695~699 (2014)[DOI]
214. Fernandez J, "Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis", Hepatology, 35, pp.140~148 (2002)[DOI]
215. 송준영, "Prognostic Significance of Infection Acquisition Sites in Spontaneous Bacterial Peritonitis: Nosocomial versus Community Acquired", Journal of Korean Medical Science, 21(4), pp.666~671 (2006), 대한의학회
216. Song KH, "Clinical outcomes of spontaneous bacterial peritonitis due to extendedspectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study", BMC Infect Dis, 9, pp.41~ (2009)[DOI]
217. Kim MJ, "Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae: a retrospective cohort study", Hepatol Int, 8, pp.582~587 (2014)[DOI]
218. Park YH, "Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea", J Gastroenterol Hepatol, 18, pp.927~933 (2003)[DOI]
219. Piano S, "The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial", Hepatology, 63, pp.1299~1309 (2016)[DOI]
220. Fernandez J, "Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study", Hepatology, 55, pp.1551~1561 (2012)[DOI]
221. Ariza X, "Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis", J Hepatol, 56, pp.825~832 (2012)[DOI]
222. Fernandez J, "Antibiotic prophylaxis in cirrhosis: good and bad", Hepatology, 63, pp.2019~2031 (2016)[DOI]
223. Jalan R, "Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013", J Hepatol, 60, pp.1310~1324 (2014)[DOI]
224. Wiest R, "Spontaneous bacterial peritonitis: recent guidelines and beyond", Gut, 61, pp.297~310 (2012)[DOI]
225. Follo A, "Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis", Hepatology, 20, pp.1495~1501 (1994)[DOI]
226. Ruiz-del-Arbol L, "Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis", Hepatology, 38, pp.1210~1218 (2003)[DOI]
227. Tandon P, "Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis", Clin Gastroenterol Hepatol, 9, pp.260~265 (2011)[DOI]
228. Sigal SH, "Restricted use of albumin for spontaneous bacterial peritonitis", Gut, 56, pp.597~599 (2007)[DOI]
229. de Araujo A, "Low-dose albumin in the treatment of spontaneous bacterial peritonitis: should we change the standard treatment?", Gut, 61, pp.1371~1372 (2012)[DOI]
230. Perez-Paramo M, "Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites", Hepatology, 31, pp.43~48 (2000)[DOI]
231. Senzolo M, "<TEX>${\beta}$<", TEX>-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis, 2009, pp.29, 1189~1193
232. Mandorfer M, "Nonselective <TEX>${\beta}$<", TEX> blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis, 2014, pp.146, 1680~1690
233. Madsen BS, "Keep the sick from harm in spontaneous bacterial peritonitis: dose of beta blockers matters", J Hepatol, 64, pp.1455~1456 (2016)[DOI]
234. Runyon BA, "Diuresis of cirrhotic ascites increases its opsonic activity and may help prevent spontaneous bacterial peri tonitis", Hepatology, 6, pp.396~399 (1986)[DOI]
235. Runyon BA, "Diuresis increases ascitic fluid opsonic activity in patients who survive spontaneous bacterial peritonitis", J Hepatol, 14, pp.249~252 (1992)[DOI]
236. Bernard B, "Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis", Hepatology, 29, pp.1655~1661 (1999)[DOI]
237. Goulis J, "Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage", Hepatology, 27, pp.1207~1212 (1998)[DOI]
238. Vivas S, "Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding", Dig Dis Sci, 46, pp.2752~2757 (2001)[DOI]
239. Chavez-Tapia NC, "Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review", Aliment Pharmacol Ther, 34, pp.509~518 (2011)[DOI]
240. Soriano G, "Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage", Gastroenterology, 103, pp.1267~1272 (1992)[DOI]
241. Fernandez J, "Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage", Gastroenterology, 131, pp.1049~1056 (2006)[DOI]
242. Llach J, "Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration", Hepatology, 16, pp.724~727 (1992)[DOI]
243. Andreu M, "Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites", Gastroenterology, 104, pp.1133~1138 (1993)[DOI]
244. Guarner C, "Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels", Gastroenterology, 117, pp.414~419 (1999)[DOI]
245. Grange JD, "Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial", J Hepatol, 29, pp.430~436 (1998)[DOI]
246. Terg R, "Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study", J Hepatol, 48, pp.774~779 (2008)[DOI]
247. Fernandez J, "Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis", Gastroenterology, 133, pp.818~824 (2007)[DOI]
248. Hanouneh MA, "The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis", J Clin Gastroenterol, 46, pp.709~715 (2012)[DOI]
249. Vlachogiannakos J, "Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis", J Gastroenterol Hepatol, 28, pp.450~455 (2013)[DOI]
250. Kang SH, "Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy", Aliment Pharmacol Ther, 46, pp.845~855 (2017)[DOI]
251. Lutz P, "Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites", PLoS One, 9, pp.e93909~ (2014)[DOI]
252. Tito L, "Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors", Hepatology, 8, pp.27~31 (1988)[DOI]
253. Gines P, "Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial", Hepatology, 12(4), pp.716~724 (1990)[DOI]
254. Bauer TM, "Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence", Dig Dis Sci, 47, pp.1356~1361 (2002)[DOI]
255. Lontos S, "A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients", J Dig Dis, 15, pp.260~267 (2014)[DOI]
256. Elfert A, "Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis", Eur J Gastroenterol Hepatol, 28, pp.1450~1454 (2016)[DOI]
257. Garcia-Tsao G, "Acute kidney injury in cirrhosis", Hepatology, 48, pp.2064~2077 (2008)[DOI]
258. 최윤정, "Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal", Clinical and Molecular Hepatology, 20(2), pp.185~191 (2014), 대한간학회[DOI]
259. Cardenas A, "Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis", Hepatology, 34(4), pp.671~676 (2001)[DOI]
260. Belcher JM, "Association of AKI with mortality and complications in hospitalized patients with cirrhosis", Hepatology, 57, pp.753~762 (2013)[DOI]
261. Bucsics T, "Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: a retrospective cohort study", J Gastroenterol Hepatol, 30, pp.1657~1665 (2015)[DOI]
262. Tsien CD, "Acute kidney injury in decompensated cirrhosis", Gut, 62, pp.131~137 (2013)[DOI]
263. Salerno F, "Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis", Gut, 56, pp.1310~1318 (2007)
264. Tan HK, "Pretransplant type 2 hepatorenal syndrome is associated with persistently impaired renal function after liver transplantation", Transplantation, 99, pp.1441~1446 (2015)[DOI]
265. Gonwa TA, "Impact of pretransplant renal function on survival after liver transplantation", Transplantation, 59, pp.361~365 (1995)[DOI]
266. Warner NS, "Acute kidney injury and chronic kidney disease in hospitalized patients with cirrhosis", J Investig Med, 59, pp.1244~1251 (2011)[DOI]
267. Wong F, "Recent advances in our understanding of hepatorenal syndrome", Nat Rev Gastroenterol Hepatol, 9, pp.382~391 (2012)[DOI]
268. Schrier RW, "Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis", Hepatology, 8, pp.1151~1157 (1988)[DOI]
269. Ruiz-del-Arbol L, "Circulatory function and hepatorenal syndrome in cirrhosis", Hepatology, 42, pp.439~447 (2005)[DOI]
270. Arroyo V, "Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management", J Hepatol, 38(Suppl 1), pp.S69~S89 (2003)
271. Ruiz-del-Arbol L, "Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine", Hepatology, 58, pp.1732~1741 (2013)[DOI]
272. Acevedo J, "Relative adrenal insufficiency in decompensated cirrhosis: relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death", Hepatology, 58, pp.1757~1765 (2013)[DOI]
273. Kim G, "Relative adrenal insufficiency in patients with cirrhosis: a systematic review and meta-analysis", Dig Dis Sci, 62, pp.1067~1079 (2017)[DOI]
274. Schrier RW, "Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis", Nephrol Dial Transplant, 27, pp.2625~2628 (2012)[DOI]
275. Low G, "Renal impairment in cirrhosis unrelated to hepatorenal syndrome", Can J Gastroenterol Hepatol, 29, pp.253~257 (2015)[DOI]
276. Wong F, "Acute kidney injury in liver cirrhosis: new definition and application", Clin Mol Hepatol, 22, pp.415~422 (2016)[DOI]
277. Orlando R, "Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis", Clin Nephrol, 51, pp.341~347 (1999)
278. Sherman DS, "Assessing renal function in cirrhotic patients: problems and pitfalls", Am J Kidney Dis, 41, pp.269~278 (2003)[DOI]
279. Caregaro L, "Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis", Arch Intern Med, 154, pp.201~205 (1994)[DOI]
280. Spencer K, "Analytical reviews in clinical biochemistry: the estimation of creatinine", Ann Clin Biochem, 23, pp.1~25 (1986)[DOI]
281. 김동진, "Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels", Clinical and Molecular Hepatology, 17(2), pp.130~138 (2011), 대한간학회
282. Angeli P, "Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites", Gut, 64, pp.531~537 (2015)[DOI]
283. Bellomo R, "Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group", Crit Care, 8, pp.R204~R212 (2004)[DOI]
284. Jenq CC, "RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients", Intensive Care Med, 33, pp.1921~1930 (2007)[DOI]
285. Cholongitas E, "RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit", J Gastroenterol Hepatol, 24, pp.1639~1647 (2009)[DOI]
286. Mehta RL, "Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury", Crit Care, 11, pp.R31~ (2007)[DOI]
287. Lassnigg A, "Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study", J Am Soc Nephrol, 15, pp.1597~1605 (2004)[DOI]
288. Tu KH, "Outcome scoring systems for short-term prognosis in critically ill cirrhotic patients", Shock, 36, pp.445~450 (2011)[DOI]
289. Radhakrishnan J, "The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient", Kidney Int, 82, pp.840~856 (2012)[DOI]
290. Pan HC, "Acute kidney injury classification for critically Ill cirrhotic patients: a comparison of the KDIGO, AKIN, and RIFLE classifications", Sci Rep, 6, pp.23022~ (2016)[DOI]
291. Angeli P, "Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance", Eur J Clin Invest, 20, pp.111~117 (1990)
292. Francoz C, "Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score", Liver Transpl, 16, pp.1169~1177 (2010)[DOI]
293. Rosi S, "New ICA criteria for the diagnosis of acute kidney injury in cirrhotic patients: can we use an imputed value of serum creatinine?", Liver Int, 35, pp.2108~2114 (2015)[DOI]
294. Wong F, "New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection", Gastroenterology, 145, pp.1280~1288 (2013)[DOI]
295. Trawale JM, "The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study", Liver Int, 30, pp.725~732 (2010)[DOI]
296. Boyer TD, "Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics", J Hepatol, 55, pp.315~321 (2011)[DOI]
297. Rodriguez E, "Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis", J Hepatol, 60, pp.955~961 (2014)[DOI]
298. Thevenot T, "Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial", J Hepatol, 62, pp.822~830 (2015)[DOI]
299. Nadim MK, "Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group", Crit Care, 16, pp.R23~ (2012)[DOI]
300. Belcher JM, "Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury", Hepatology, 60, pp.622~632 (2014)[DOI]
301. Sola-Vera J, "Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites", Hepatology, 37, pp.1147~1153 (2003)[DOI]
302. Elia C, "Severe acute kidney injury associated with non-steroidal antiinflammatory drugs in cirrhosis: a case-control study", J Hepatol, 63, pp.593~600 (2015)[DOI]
303. Akriviadis E, "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial", Gastroenterology, 119, pp.1637~1648 (2000)[DOI]
304. Thursz MR, "Prednisolone or pentoxifylline for alcoholic hepatitis", N Engl J Med, 372, pp.1619~1628 (2015)[DOI]
305. Dong T, "Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis", Dig Dis Sci, 61, pp.3621~3626 (2016)[DOI]
306. Sharma BC, "A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy", Am J Gastroenterol, 108, pp.1458~1463 (2013)[DOI]
307. Salerno F, "Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis", BMC Gastroenterol, 15, pp.167~ (2015)[DOI]
308. Wong F, "Drug insight: the role of albumin in the management of chronic liver disease", Nat Clin Pract Gastroenterol Hepatol, 4, pp.43~51 (2007)[DOI]
309. Garcia-Martinez R, "Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications", Hepatology, 58, pp.1836~1846 (2013)[DOI]
310. Garcia-Martinez R, "Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury", Liver Int, 35, pp.335~343 (2015)[DOI]
311. Neri S, "Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome", Dig Dis Sci, 53, pp.830~835 (2008)[DOI]
312. Martin-Llahi M, "Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study", Gastroenterology, 134, pp.1352~1359 (2008)[DOI]
313. Ortega R, "Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study", Hepatology, 36(4), pp.941~948 (2002)[DOI]
314. Rodriguez E, "Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: effects on kidney function and transplantation outcomes", Liver Transpl, 21, pp.1347~1354 (2015)[DOI]
315. Sanyal AJ, "A randomized, prospective, double-blind, placebocontrolled trial of terlipressin for type 1 hepatorenal syndrome", Gastroenterology, 134, pp.1360~1368 (2008)[DOI]
316. Sanyal AJ, "Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.", Aliment Pharmacol Ther, 45, pp.1390~1402 (2017)[DOI]
317. Egerod Israelsen M, "Acute kidney injury and hepatorenal syndrome in cirrhosis", J Gastroenterol Hepatol, 30, pp.236~243 (2015)[DOI]
318. Cavallin M, "Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study", Hepatology, 63, pp.983~992 (2016)[DOI]
319. Nazar A, "Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome", Hepatology, 51, pp.219~226 (2010)[DOI]
320. Facciorusso A, "Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis", Lancet Gastroenterol Hepatol, 2, pp.94~102 (2017)[DOI]
321. Sharma P, "An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response", Am J Gastroenterol, 103, pp.1689~1697 (2008)[DOI]
322. Singh V, "Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study", J Hepatol, 56, pp.1293~1298 (2012)[DOI]
323. Nassar Junior AP, "Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis", PLoS One, 9, pp.e107466~ (2014)[DOI]
324. Nadim MK, "Corrigendum to "Management of the critically ill patients with cirrhosis: a multidisciplinary perspective"", J Hepatol (2016)[DOI]
325. Wong F, "Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome", Hepatology, 40, pp.55~64 (2004)
326. Esrailian E, "Octreotide", midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome, 2007, pp.52, 742~748
327. Skagen C, "Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome", J Clin Gastroenterol, 43, pp.680~685 (2009)[DOI]
328. Cavallin M, "Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial", Hepatology, 62, pp.567~574 (2015)[DOI]
329. Wong LP, "Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy", Kidney Int, 68, pp.362~370 (2005)[DOI]
330. Zhang Z, "Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin", J Crit Care, 30, pp.969~974 (2015)[DOI]
331. Guevara M, "Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems", Hepatology, 28, pp.416~422 (1998)[DOI]
332. Rossle M, "TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update", Gut, 59, pp.988~1000 (2010)[DOI]
333. Brensing KA, "Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study", Gut, 47, pp.288~295 (2000)[DOI]
334. Senzolo M, "Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome", Eur J Gastroenterol Hepatol, 18, pp.1143~1150 (2006)
335. Wong F, "Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites", Ann Intern Med, 122, pp.816~822 (1995)[DOI]
336. Trebicka J, "Emergency TIPS in a child-pugh B patient: when does the window of opportunity open and close?", J Hepatol, 66, pp.442~450 (2017)[DOI]
337. Jalan R, "Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis", J Hepatol, 38, pp.24~31 (2003)
338. Mitzner SR, "Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial", Liver Transpl, 6, pp.277~286 (2000)[DOI]
339. Wong F, "Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment", Gut, 59, pp.381~386 (2010)[DOI]
340. Nair S, "Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation", Hepatology, 35, pp.1179~1185 (2002)[DOI]
341. Marik PE, "The course of type 1 hepato-renal syndrome post liver transplantation", Nephrol Dial Transplant, 21, pp.478~482 (2006)[DOI]
342. Wong F, "Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation", Liver Transpl, 21, pp.300~307 (2015)[DOI]
343. Boyer TD, "Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1", Liver Transpl, 17, pp.1328~1332 (2011)[DOI]
344. Goldaracena N, "Living vs. deceased donor liver transplantation provides comparable recovery of renal function in patients with hepatorenal syndrome: a matched case-control study", Am J Transplant, 14, pp.2788~2795 (2014)[DOI]
345. Lee JP, "Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation", Liver Transpl, 18, pp.1237~1244 (2012)[DOI]
346. Malagari K, "Cirrhosis-related intrathoracic disease. Imaging features in 1038 patients", Hepatogastroenterology, 52, pp.558~562 (2005)
347. Strauss RM, "Hepatic hydrothorax", Semin Liver Dis, 17, pp.227~232 (1997)[DOI]
348. Huang PM, "The morphology of diaphragmatic defects in hepatic hydrothorax: thoracoscopic finding", J Thorac Cardiovasc Surg, 130, pp.141~145 (2005)[DOI]
349. Machicao VI, "Pulmonary complications in chronic liver disease", Hepatology, 59, pp.1627~1637 (2014)[DOI]
350. Mirouze D, "Left pleural effusion in patients with chronic liver disease and ascites. Prospective study of 22 cases", Dig Dis Sci, 26, pp.984~988 (1981)[DOI]
351. Xiol X, "Usefulness and complications of thoracentesis in cirrhotic patients", Am J Med, 111, pp.67~69 (2001)[DOI]
352. Gurung P, "Pleural fluid analysis and radiographic, sonographic, and echocardiographic characteristics of hepatic hydrothorax", Chest, 140, pp.448~453 (2011)[DOI]
353. Xiol X, "Spontaneous bacterial empyema in cirrhotic patients: a prospective study", Hepatology, 23, pp.719~723 (1996)[DOI]
354. Chen TA, "Risk factors for spontaneous bacterial empyema in cirrhotic patients with hydrothorax", J Chin Med Assoc, 66, pp.579~586 (2003)
355. Sese E, "Low complement levels and opsonic activity in hepatic hydrothorax: its relationship with spontaneous bacterial empyema", J Clin Gastroenterol, 36, pp.75~77 (2003)[DOI]
356. Xiol X, "Liver transplantation in patients with hepatic hydrothorax", Transpl Int, 18, pp.672~675 (2005)[DOI]
357. Feller-Kopman D, "Large-volume thoracentesis and the risk of reexpansion pulmonary edema", Ann Thorac Surg, 84, pp.1656~1661 (2007)[DOI]
358. Siegerstetter V, "Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients", Eur J Gastroenterol Hepatol, 13, pp.529~534 (2001)[DOI]
359. Gordon FD, "The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt", Hepatology, 25, pp.1366~1369 (1997)[DOI]
360. Dhanasekaran R, "Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis", Am J Gastroenterol, 105, pp.635~641 (2010)[DOI]
361. Spencer EB, "Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax", J Vasc Interv Radiol, 13, pp.385~390 (2002)[DOI]
362. Chalasani N, "Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting", Gastroenterology, 118, pp.138~144 (2000)[DOI]
363. Milanez de Campos JR, "Thoracoscopy and talc poudrage in the management of hepatic hydrothorax", Chest, 118, pp.13~17 (2000)[DOI]
364. Ferrante D, "Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax", Am J Gastroenterol, 97, pp.3172~3175 (2002)[DOI]
365. Runyon BA, "Hepatic hydrothorax is a relative contraindication to chest tube insertion", Am J Gastroenterol, 81, pp.566~567 (1986)
366. Orman ES, "Outcomes of patients with chest tube insertion for hepatic hydrothorax", Hepatol Int, 3, pp.582~586 (2009)[DOI]
367. Singh A, "Evidence-based review of the management of hepatic hydrothorax", Respiration, 86, pp.155~173 (2013)[DOI]
368. Baker EM, "Management of recurrent pleural effusions with a tunneled catheter", Heart Lung, 39, pp.314~318 (2010)[DOI]
369. Chalhoub M, "The use of the pleurX catheter in the management of non-malignant pleural effusions", Chron Respir Dis, 8, pp.185~191 (2011)[DOI]
370. Herlihy JP, "PleurX catheter for the management of refractory pleural effusions in congestive heart failure", Tex Heart Inst J, 36, pp.38~43 (2009)
371. Belghiti J, "Abdominal wall hernias in the setting of cirrhosis", Semin Liver Dis, 17, pp.219~226 (1997)[DOI]
372. Odom SR, "Emergency hernia repair in cirrhotic patients with ascites", J Trauma Acute Care Surg, 75, pp.404~409 (2013)[DOI]
373. Byung Chul Yu, "The repair of umbilical hernia in cirrhotic patients: 18 consecutive case series in a single institute", Annals of Surgical Treatment and Research, 89(2), pp.87~91 (2015), 대한외과학회
374. Young Hoe Hur, "Inguinal hernia repair in patients with liver cirrhosis accompanied by ascites", Annals of Surgical Treatment and Research, 80(6), pp.420~425 (2011), 대한외과학회
375. Runyon BA, "Natural history of repaired umbilical hernias in patients with and without ascites", Am J Gastroenterol, 80, pp.38~39 (1985)
376. Telem DA, "Complicated hernia presentation in patients with advanced cirrhosis and refractory ascites: management and outcome", Surgery, 148, pp.538~543 (2010)[DOI]
377. Lewis JH, "Review article: prescribing medications in patients with cirrhosis - a practical guide", Aliment Pharmacol Ther, 37, pp.1132~1156 (2013)[DOI]
378. Verbeeck RK, "Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction", Eur J Clin Pharmacol, 64, pp.1147~1161 (2008)[DOI]
379. Elbekai RH, "The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes", Curr Drug Metab, 5, pp.157~167 (2004)[DOI]
380. Krahenbuhl S, "Pharmacokinetics and pharmacodynamics in cirrhosis", Medicine, 30, pp.24~27 (2002)[DOI]
381. Villeneuve JP, "Furosemide kinetics and dynamics in patients with cirrhosis", Clin Pharmacol Ther, 40, pp.14~20 (1986)[DOI]
382. Chalasani N, "Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts", Hepatology, 34, pp.1103~1108 (2001)[DOI]
383. Vuppalanchi R, "Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt", J Clin Gastroenterol, 45, pp.638~642 (2011)[DOI]
384. 홍영미, "The Prescription Pattern of Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs in Patients with Liver Cirrhosis", Journal of Korean Medical Science, 31(10), pp.1604~1610 (2016), 대한의학회
385. Ahn BM, "Acetaminophen-induced acute hepatic failure", J Korean Med Assoc, 49, pp.846~883 (2006)[DOI]
386. Manyike PT, "Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation", Clin Pharmacol Ther, 67, pp.275~282 (2000)[DOI]
387. Chandok N, "Pain management in the cirrhotic patient: the clinical challenge", Mayo Clin Proc, 85, pp.451~458 (2010)[DOI]
388. De Ledinghen V, "Anti-inflammatory drugs and variceal bleeding: a case-control study", Gut, 44, pp.270~273 (1999)[DOI]
389. Bosilkovska M, "Analgesics in patients with hepatic impairment: pharmacology and clinical implications", Drugs, 72, pp.1645~1669 (2012)[DOI]
390. Claria J, "Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites", Hepatology, 41, pp.579~587 (2005)[DOI]
391. Williams RL, "Naproxen disposition in patients with alcoholic cirrhosis", Eur J Clin Pharmacol, 27, pp.291~296 (1984)[DOI]
392. Hayes PC, "Meta-analysis of value of propranolol in prevention of variceal haemorrhage", Lancet, 336, pp.153~156 (1990)[DOI]
393. Homeida M, "Decreased first-pass metabolism of labetalol in chronic liver disease", Br Med J, 2, pp.1048~1050 (1978)[DOI]
394. Ge PS, "The changing role of beta-blocker therapy in patients with cirrhosis", J Hepatol, 60, pp.643~653 (2014)[DOI]
395. Leithead JA, "Non-selective <TEX>${\beta}$<", TEX>-blockers are associated with improved survival in patients with ascites listed for liver transplantation, 2015, pp.64, 1111~1119
396. Mookerjee RP, "Treatment with non-selective beta-blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure", J Hepatol, 64, pp.574~582 (2016)[DOI]
397. Franz CC, "Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis", Eur J Clin Pharmacol, 68, pp.179~188 (2012)[DOI]
398. Lucena MI, "Drug use for non-hepatic associated conditions in patients with liver cirrhosis", Eur J Clin Pharmacol, 59, pp.71~76 (2003)[DOI]
399. Gentilini P, "Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver", Gastroenterology, 104, pp.588~594 (1993)[DOI]
400. Pariente EA, "Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites", Gastroenterology, 88(5), pp.1255~1259 (1985)[DOI]
401. Lewis JH, "Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebocontrolled, multicenter trial", Hepatology, 46, pp.1453~1463 (2007)[DOI]
402. Athyros VG, "Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis", Lancet, 376, pp.1916~1922 (2010)[DOI]
403. Chang FM, "Statins decrease the risk of decompensation in hepatitis B virusand hepatitis C virus-related cirrhosis: a population-based study", Hepatology, 66, pp.896~907 (2017)[DOI]
404. Kim RG, "Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 15, pp.1521~1530 (2017)[DOI]
405. Simon TG, "Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C", J Hepatol, 62, pp.18~23 (2015)[DOI]
406. Tsan YT, "Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection", J Clin Oncol, 30, pp.623~630 (2012)[DOI]
407. Abraldes JG, "Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis", Gastroenterology, 150, pp.1160~1170 (2016)[DOI]
408. "Drug Information Handbook" (2017), Wolters Kluwer Clinical Drug Information, Inc.
409. Dam G, "Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites", Hepatology, 64, pp.1265~1272 (2016)
410. Xu HB, "Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis", Genet Mol Res, 14, pp.7490~7501 (2015)[DOI]
411. Goel GA, "Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression", Clin Gastroenterol Hepatol, 10, pp.422~427 (2012)[DOI]
412. Deshpande A, "Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis", Clin Gastroenterol Hepatol, 10, pp.225~233 (2012)[DOI]
413. Bajaj JS, "Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis", Aliment Pharmacol Ther, 36, pp.866~874 (2012)[DOI]
414. Tsai CF, "Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study", Gastroenterology, 152, pp.134~141 (2017)[DOI]
415. Vaezi MF, "Complications of proton pump inhibitor therapy", Gastroenterology, 153, pp.35~48 (2017)[DOI]

관련 논문AI추천